Untapped Health Systems CognifiSense's VRNT is already prescribed and reimbursed across Workers' Comp, VA, and Medicare channels, indicating strong payer acceptance and potential expansion into additional government and private payer programs to scale adoption in other pain management settings.

Neuroscience Edge The FDA-cleared, evidence-based approach that retrains the brain addresses central sensitization and delivers measurable brain changes, creating a competitive differentiator for sales conversations with clinics, employers, and insurers seeking non-opioid, long-term pain solutions.

Home Delivery Model A home-based 8-week VR therapy program offers convenience and potential cost savings, appealing to employers and workers’ compensation programs seeking scalable, remote treatment options with consistent adherence and measurable outcomes.

Evidence-backed ROI Peer-reviewed trial results showing reductions in pain interference and durable benefits support value-based selling to health plans and large employers focused on reducing opioid use, improving productivity, and lowering total cost of care.

Growth Readiness Small but scalable organization with a clear product-market fit in medical equipment/therapeutics and a tech stack aligned to modern digital health deployments, presenting a pathway for channel partnerships, white-labeling, or OEM collaborations to accelerate market reach.